Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Ines Chamakhi"'
Autor:
Eliane Nguyen, Sarit Assouline, Harold J. Olney, Natasha Szuber, Michaël Harnois, Ines Chamakhi, Luigina Mollica, Lambert Busque, Shireen Sirhan
Publikováno v:
Blood. 136:4-7
Background: Since lowering the hemoglobin (Hb) and hematocrit (Hct) diagnostic thresholds for polycythemia vera (PV) to 165 g/L and 49% in men and 160 g/L and 48% in women respectively, by the World Health Organization (WHO) in 2016 (Blood. 2016;127:
Autor:
Guy Sauvageau, Jean Roy, Ines Chamakhi, Nathalie Dhedin, Robert Bélanger, Denis-Claude Roy, Lambert Busque, Claude Perreault, Thierry Ducruet, Douglas N. Fish
Publikováno v:
Experimental Hematology. 34:107-114
Risk factors of acute graft-vs-host disease (GVHD) following allogeneic bone marrow transplantation have been well described before. In this study, we tested the hypothesis that acute GVHD after allogeneic peripheral blood stem cell (PBSC) transplant
Autor:
Alexa Del Corpo, Harold J. Olney, Adi J. Klil-Drori, Hui Yin, Lambert Busque, Michel-Olivier Gratton, Sarit Assouline, Michaël Harnois, Robert Delage, Luigina Mollica, Pierre Laneuville, Laurent Azoulay, Ines Chamakhi
Publikováno v:
Blood. 128:3072-3072
Background: Timely molecular monitoring is the cornerstone of chronic myeloid leukemia (CML) treatment guidelines. These guidelines are based on the design of clinical trials, but none have been validated prospectively. We hypothesized that timely mo
Autor:
Harold J. Olney, Adi J. Klil-Drori, Pierre Laneuville, Michaël Harnois, Ines Chamakhi, Laurent Azoulay, Michel-Olivier Gratton, Sarit Assouline, Lambert Busque, Luigina Mollica, Hui Yin, Robert Delage
Publikováno v:
Blood. 126:2778-2778
Background: Generic versions of imatinib (GEN) have been approved for use in Canada for chronic myeloid leukemia, chronic phase (CML-CP) on the basis of bioequivalence studies and were reimbursed in Québec starting from October 2013. Molecular respo